GLP-1RA PHARMACOKINETICS AND CLINICAL EFFECTS: FOCUS ON CARDIAC, VASCULAR, AND GLOMERULAR STRUCTURES.
INTRODUCTION Glucagon-like peptide-1 receptor agonists (GLP-1RA) have emerged as key drug class in the management of the cardio-nephro-metabolic continuum. Their effects extend to cardiac, vascular, and renal systems, providing a pathophysiological basis for the results of cardiovascular outcomes trials. Their pharmacokinetic properties substantially contribute, as structural modifications prolonged plasma half-life and increased systemic exposure through resistance to enzymatic degradation, albumin binding, and optimization of molecular size. AREAS COVERED This review integrates current evidence on pharmacokinetics, pharmacodynamics, and clinical effects of GLP-1RA focusing on the heart, vascular system, and kidney. A literature search until March 2026 was performed using MEDLINE, EMBASE, Google Scholar, Web of Science, and the Cochrane Controlled Trials Register. GLP-1RA exert modest chronotropic effects and cardiac protection in ischemia-reperfusion, although direct myocardial effects remain incompletely defined. Vascular benefits seem mediated by improved endothelial function, reduced oxidative stress, and modulation of nitric oxide pathways. In the kidney, GLP-1RA modulate proximal tubular sodium reabsorption and tubule-glomerular feedback, leading to reduced albuminuria and slower renal function decline. Clinical trials and meta-analyses documented reductions in major cardiovascular and renal outcomes. EXPERT OPINION In our view, pharmacokinetics is a major determinant of the clinical profile of GLP-1RA, beyond glycemic control alone.